Table 2.

Dosing regimen for in vivo antigen administration.

	Amount of BSA (µg)
Group	First dose	Second dose	Third dose	Total
Formulation C (0.5% BSA, 7–17 kDa PLGA)a	22	20	22	64
Formulation G (0.5% BSA, 24–38 kDa PLGA)a	23	14	34	71
Low Dose Bolus BSA	22	22	22	66
Formulation E (5% BSA, 24–38 kDa PLGA)a	298	68	65	431
High Dose Bolus BSA	298	68	65	431
Empty PLGA microspheres, 7–17 kDa	0	0	0	0
Empty PLGA microspheres, 24–38 kDa	0	0	0	0
Saline	0	0	0	0

All PLGA used in vivo was 50:50.

^aIndicates theoretical dose based on in vitro results.